Evidence map›Paper›PMID 35060430›Full record

Observational studyActa oncologica (Stockholm, Sweden)2022

The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients.

Sonja Stieb, Grete M Engeseth, Abdallah S R Mohamed, Renjie He, Ismael Perez-Martinez, Stockton Rock, Tanaya S Deshpande, Adam S Garden, David I Rosenthal, Steven J Frank and 2 more

Open access · diamondAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Acta oncologica (Stockholm, Sweden), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Sonja StiebDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Grete M EngesethHaukeland University Hospital, Bergen, Norway.
Abdallah S R MohamedDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Renjie HeDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ismael Perez-MartinezDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stockton RockDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tanaya S DeshpandeDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adam S GardenDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David I RosenthalDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steven J FrankDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G Brandon GunnDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C David FullerDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USHaukeland University Hospital · NOKantonsspital Aarau · CH

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MILLS, GORDON B. · 2002 to 2012
$26.1M
Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac deviceR01DE028290 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHRISTODOULEAS, JOHN PAUL, FULLER, CLIFTON DAVID · 2019 to 2023
$4.3M
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR01DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2016 to 2020
$2.9M
SMART-ACT: Spatial Methodologic Approaches for Risk Assessment and Therapeutic Adaptation in Cancer TreatmentR01CA214825 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2017 to 2019
$1.1M
imaging Radiation-Associated Dysphagia (iRAD)R01CA218148 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FULLER, CLIFTON DAVID, HUTCHESON, KATHERINE ARNOLD · 2017 to 2019
$810k
Fellow and Resident Radiation Oncology iNtensive Training in Imaging and Informatics to Empower Research Careers (FRONTI2ER)R25EB025787 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAS, PRAJNAN, FULLER, CLIFTON DAVID · 2018 to 2022
$535k
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR56DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2015 to 2015
$470k
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097007NCI NIH HHS R01 CA214825NCI NIH HHS R01 CA218148NIBIB NIH HHS R25 EB025787NIDCR NIH HHS R01 DE025248NIDCR NIH HHS R01 DE028290NIDCR NIH HHS R56 DE025248
6 · The paper itself

Abstract

backgroundTo analyze the influence of radiation dose on late radiation-associated taste impairment in oropharyngeal cancer (OPC) patients treated with intensity-modulated radiotherapy (IMRT) using the taste bud bearing tongue mucosa as organ at risk. MATERIAL AND

methodsThis study is part of an ongoing, prospective observational study. Cancer-free OPC survivors with at least 24 months from IMRT were included in this analysis. Scores for taste impairment and dry mouth were extracted from the MD Anderson Symptom Inventory Head and Neck module (MDASI-HN) with scores of ≥5 considered as moderate-to-severe symptoms. The mean dose, minimum and maximum dose to the taste bud bearing tongue mucosa, the ipsi- and contralateral parotid and submandibular glands were extracted and analyzed for correlation with moderate-to-severe taste impairment.

resultsOne hundred sixteen T1-4 OPC patients were included (81% males, median age: 55). The primary tumor was in the tonsil in 92 cases (79%) and in the base of tongue in 21 cases (18%). Patients were treated with 64.2-72.0 Gy; 37 patients (32%) received concurrent chemotherapy and 22 (19%) concurrent targeted therapy. After a median of 58 months from RT (IQR: 43-68) 38 patients (33%) suffered from moderate-to-severe long-term radiation-associated taste impairment. No dose volume parameter of the taste bud bearing tongue mucosa and the salivary glands was significantly associated with moderate-to-severe taste impairment for the whole patient cohort. For patients without concurrent chemotherapy, the minimum and mean dose to the ipsilateral parotid gland, and the maximum dose to the submandibular gland was significantly associated with late taste impairment (all

conclusionThe dose to the ipsilateral parotid gland seems to play an important role in the development of late taste impairment. The influence of dose to the taste bud bearing tongue mucosa remains unclear and needs further investigation.

Indexed as

Head and Neck NeoplasmsOropharyngeal NeoplasmsFemaleHumansMaleMiddle AgedProspective StudiesRadiation DosageTasteHead and neck neoplasmsoropharyngeal cancerradiotherapytaste

Identifiers

PMID35060430
PMCPMC8981169
OpenAlexW4205703887

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.